With Astellas, Roche and Celgene all spending big sums to acquire ground-breaking biotech outfits, Epsilon Economics’ Grace Park and Mohan Rao look at the best ways to get IP value for money in an ambitious market
23 Jul
2020
With Astellas, Roche and Celgene all spending big sums to acquire ground-breaking biotech outfits, Epsilon Economics’ Grace Park and Mohan Rao look at the best ways to get IP value for money in an ambitious market
